| __timestamp | Catalyst Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 2983000000 |
| Thursday, January 1, 2015 | 8597010 | 3426000000 |
| Friday, January 1, 2016 | 7910260 | 3398000000 |
| Sunday, January 1, 2017 | 7304399 | 3878000000 |
| Monday, January 1, 2018 | 15875961 | 4056000000 |
| Tuesday, January 1, 2019 | 36881187 | 4381000000 |
| Wednesday, January 1, 2020 | 44233754 | 5151000000 |
| Friday, January 1, 2021 | 49628000 | 5246000000 |
| Saturday, January 1, 2022 | 58183000 | 5673000000 |
| Sunday, January 1, 2023 | 133710000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Gilead, a giant in the sector, consistently reported SG&A expenses in the billions, peaking at $6.09 billion in 2023. This represents a steady increase of approximately 104% from 2014. In contrast, Catalyst Pharmaceuticals, a smaller player, saw a dramatic rise in SG&A expenses, skyrocketing by nearly 2,889% from 2014 to 2023, reaching $133.71 million. This stark difference highlights the varied strategies and growth trajectories of these companies. While Gilead's expenses reflect its expansive operations, Catalyst's surge indicates aggressive scaling and market penetration efforts. Understanding these trends offers valuable insights into the strategic priorities and operational challenges faced by pharmaceutical companies today.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Insmed Incorporated or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared